LIT for Recurrent Pregnancy Loss in India: What Lymphocyte Immunotherapy Involves | ALIV

Recurrent pregnancy loss — the experience of two or more consecutive pregnancy losses — affects approximately 1–2% of couples attempting conception and represents one of the most emotionally devastating clinical experiences in reproductive medicine. A significant proportion of recurrent pregnancy loss cases have an immunological component: the maternal immune system fails to establish the tolerance necessary to accept the genetically distinct (50% paternal) embryo as "self" — and mounts an immune rejection response that disrupts early implantation or placentation. Lymphocyte Immunization Therapy (LIT) is a specialised reproductive immunology intervention aimed at inducing this maternal tolerance in appropriately selected patients.

The Immunological Basis of Immune-Mediated Pregnancy Loss

Normal pregnancy requires a remarkable immune adaptation: the maternal immune system must tolerate the presence of paternally-derived alloantigens on the embryo and placenta — genetic material that is "foreign" by every immunological criterion but must not be rejected. This tolerance is mediated by specialised regulatory mechanisms involving: uterine natural killer cells (uNK cells — which in normal pregnancy adopt a regulatory rather than cytotoxic phenotype in the implantation zone); regulatory T-cells (Tregs — which suppress the effector immune responses that would otherwise target the paternal antigens); and blocking antibodies that bind paternal HLA antigens and prevent maternal effector immune cells from recognising the embryo as a target.

In a subset of recurrent pregnancy loss patients, these tolerance mechanisms are inadequate — producing what is sometimes called "immunological rejection" of the pregnancy. The specific patterns associated with immune-mediated pregnancy loss include: deficiency of blocking antibodies against paternal HLA antigens; elevated natural killer cell activity in the peripheral blood and/or uterine lining; and inadequate Treg expansion in response to the embryo. LIT addresses the blocking antibody deficiency specifically — a targeted intervention for a specific immunological mechanism. It is not a treatment for all causes of pregnancy loss. See the broader reproductive context: PCOS and fertility planning and the reproductive medicine overview.

What LIT Involves

LIT involves the preparation of a suspension of the partner's (or donor's) lymphocytes (white blood cells) — isolated from a blood sample — and administering this suspension as an intradermal injection to the female partner. The maternal immune system is exposed to paternal lymphocytes carrying paternal HLA antigens and is stimulated to develop the blocking antibody response and Treg expansion that constitutes immunological tolerance. The immunisation is typically administered as a series of injections at defined intervals in the months before a planned conception attempt or embryo transfer. A blood test — the crossmatch test or mixed lymphocyte reaction assay — is used to confirm the development of blocking antibodies before proceeding with pregnancy attempts.

LIT at ALIV is provided under the clinical supervision of Dr. Sunita Tandulwadkar and the reproductive immunology team — a specialised assessment that requires detailed investigation of the specific immunological pattern before any treatment decision. Not all recurrent pregnancy loss has an immune component; the clinical workup must exclude other causes (chromosomal abnormalities in the couple or embryo, uterine structural abnormalities, antiphospholipid syndrome, thrombophilia, and thyroid and metabolic factors) before LIT is considered. LIT for recurrent pregnancy loss without this workup is not responsible clinical practice.

The Evidence and the Regulatory Context

LIT has a contested history in evidence-based medicine. Early RCTs produced mixed results; subsequent meta-analyses have shown benefit in specific populations — particularly those with demonstrated inadequate blocking antibody response. The Cochrane review on immunotherapy for recurrent miscarriage has been updated multiple times and reflects the evidence uncertainty. In India, LIT is not standardly regulated as a pharmaceutical product — it is a clinical procedure using autologous or allogeneic lymphocytes. ALIV offers LIT within a full reproductive immunological assessment framework, with complete informed consent about the evidence quality and the experimental nature of the intervention. Dr. Tandulwadkar's clinical judgement guides patient selection based on the specific immunological profile identified at workup.

How is it determined whether I am a LIT candidate?

The LIT workup at ALIV includes: recurrent pregnancy loss history and obstetric assessment; chromosomal karyotyping of both partners; antiphospholipid antibody panel; thrombophilia screen; uterine evaluation (sonohysterogram or hysteroscopy); thyroid function; NK cell assay (peripheral blood NK cell percentage and activity); and crossmatch/blocking antibody assessment. Only patients with a specific immunological pattern — particularly those with inadequate blocking antibodies and elevated NK cell activity without other dominant causes — are recommended for LIT. The assessment takes one to two months to complete comprehensively.

Is LIT safe for the male partner who provides the lymphocytes?

The lymphocyte donation requires a routine blood draw — typically 40–60ml of venous blood — from the male partner. This is safe, has no meaningful health impact, and is performed at ALIV's clinic under standard phlebotomy conditions. The male partner does not undergo any procedure beyond the blood draw.

Is a single course of LIT sufficient?

LIT protocols vary by clinical response. Many patients undergo an initial series of two to four injections at monthly intervals, with blocking antibody status reassessed before conception attempts. Some patients require a booster injection with each subsequent pregnancy attempt to maintain immunological priming. The specific protocol is determined by the immunological response documented on follow-up crossmatch testing — Dr. Tandulwadkar's team guides the timing based on the individual's immunological trajectory